FEIBA(R) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre

SMEJKAL, Petr, Petr BRABEC, Miloslava MATÝŠKOVÁ, Alena BULIKOVÁ, Marie ŠLECHTOVÁ, Jarmila KISSOVÁ, Gabriela CHLUPOVÁ, Jan MUŽÍK and Miroslav PENKA. FEIBA(R) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia. 2009, vol. 15, No 3, p. 743-751. ISSN 1351-8216.

Basic information

Original name

FEIBA(R) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre

Name in Czech

FEIBA(R) v léčbě akutního krvácení u pacientů s hemofilií A a inhibitorem faktoru VIII: retrospektivní studie regionálního centra

Authors

SMEJKAL, Petr (203 Czech Republic, guarantor), Petr BRABEC (203 Czech Republic), Miloslava MATÝŠKOVÁ (203 Czech Republic), Alena BULIKOVÁ (203 Czech Republic), Marie ŠLECHTOVÁ (203 Czech Republic), Jarmila KISSOVÁ (203 Czech Republic), Gabriela CHLUPOVÁ (203 Czech Republic), Jan MUŽÍK (203 Czech Republic) and Miroslav PENKA (203 Czech Republic)

Edition

Haemophilia, 2009, 1351-8216

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.505

RIV identification code

RIV/00216224:14110/09:00036074

Organization unit

Faculty of Medicine

UT WoS

000265409600013

Keywords in English

haemophilia; bleeding; FEIBA

Tags

bleeding, FEIBA, haemophilia

---

Abstract

V originále

FEIBA(R) is used to achieve haemostasis in haemophiliacs with inhibitor. The aim of this study was to evaluate efficacy and consumption of the product in treatment of haemorrhages in haemophiliacs with factor VIII inhibitor, and determine factors that can influence the results of treatment. We used data from our haemophilia centre from years 2000-2008. Six haemophiliacs with factor VIII inhibitor were treated on demand with FEIBA(R) for 61 bleeding episodes (45 haemarthroses, six muscle bleeds, six other sites bleeds and four multiple sites bleeds).

In Czech

FEIBA(R) is used to achieve haemostasis in haemophiliacs with inhibitor. The aim of this study was to evaluate efficacy and consumption of the product in treatment of haemorrhages in haemophiliacs with factor VIII inhibitor, and determine factors that can influence the results of treatment. We used data from our haemophilia centre from years 2000-2008. Six haemophiliacs with factor VIII inhibitor were treated on demand with FEIBA(R) for 61 bleeding episodes (45 haemarthroses, six muscle bleeds, six other sites bleeds and four multiple sites bleeds).